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Introduction
Poor healing is observed around stent grafts (SG) used for the endovascular treatment of abdominal aortic aneurysms (AAA) [1] , with a lack of organized tissue formation in the cavity and absence of incorporation of the polymer graft into the surrounding wall of the blood vessel [1, 2] . This can be related to three main factors: (i) the pro-apoptotic environment of a diseased aneurysmal vessel, characterized by changes in extracellular matrix composition, presence of inflammatory cells, vascular cell depletion [3, 4] ; (ii) the lack of oxygen and nutrients after SG insertion; and (iii) the nature of the materials used for SG cover, namely polyethylene terephtalate (PET) or poly(tetrafluoroethylene) (PTFE). The deficit of tissue formation on the SG abluminal side could play a role in the occurrence of type I endoleaks and endotension (defined by a sac enlargement of more than 5mm without visible leak) that affect respectively 13 and 18 % of patients treated by SG. [5, 6] Presence of bare stent, hooks or barbs at proximal neck helps preventing SG migration, which is observed in 1 to 3% of cases, by providing strong mechanical attachment to the vessel [2, 5, 6] . However, they do not promote complete biological seal at proximal and distal necks and thus cannot prevent neck dilatation associated with delayed endoleak [7, 8] .
We hypothesize that modification of SG surface properties via the immobilization of biomolecules could counter aneurysmal degeneration and promote healing around the abluminal side of the SG, thereby preventing late occurence of type I endoleaks and migration of SG through biological seal. The general aims of our work were to develop a bioactive coating that can counter the pro-apoptotic environment observed in the aneurysm sac while promoting colonization of the implant by SMC and fibroblasts, and to demonstrate the potential of such a coating to improve tissue growth at the SG external surface.
Materials and Methods
Two different bioactive molecules were selected to create a bioactive coating: (i) chondroitin sulfate (CS), a glycosaminoglycan of the extracellular matrix that participates in the integrity of the arterial wall in normal aortas [9] and exhibits anti-apoptotic properties [10] ; and (ii) epidermal growth factor (EGF), a major actor of wound-healing [11] presenting both anti-apoptotic and pro-proliferative properties [12, 13] . This choice is based on previous studies that have shown the superiority of the combination of CS and EGF [14] . The coating was created on polyethylene terephtalate (PET) and expanded polytetrafluoroethylene (ePTFE) substrates (since these are the two plastic materials used in SG graft fabric) and tested in vitro for its bioactivity on vascular cells and its stability.
Then, in vivo testing on a canine iliac aneurysm model was performed for its ability to induce sustained healing in the aneurysmal cavity [15] when coating the external surface of an expanded PTFE-based commercial SG.
Bioactive coating preparation
Before grafting CS and EGF covalently, primary amine (NH 2 ) groups were created on the polymer substrates by means of a 100 nm-thick coating of (NH 2 )-rich plasma polymer, here designated as LP, which was deposited using a low-pressure radiofrequency glow discharge reactor [16] . Then, the immobilization of CS and EGF on LP surfaces was 
Chemical and Mechanical Characterization
Surface composition of the coating on ePTFE was characterized using X-ray photoelectron spectroscopy (XPS, VG ESCALAB 3MkII instrument). The wettability of the various coatings was assessed by static water contact angle (WCA) measurements, using Milli-Q water (VCA OptimaXE, AST products). Scanning electron microscopy (SEM, Hitachi S-3600N) was used to evaluate whether coating deposition altered the surface morphology and porosity of the ePTFE substrate. Finally, traction tests were carried out using a Bose Electroforce 3200 system (Eden Prairie, MN) with a deformation rate of 5%/s, in order to confirm that coating deposition did not affect the mechanical properties (Young's modulus, E, and tensile strength) of ePTFE.
Biological characterization
Cell culture materials. 
Cell survival on PET films.
Cells were seeded on bare and coated PET films (50 μm thick, Goodfellow, Huntingdon, England), at 40 000 cells/ cm 2 in complete growth medium. 24h after initial cell seeding, the surfaces were washed with PBS and serum-free medium was added. At each timepoint, cell metabolic activity was probed using the alamarBlue assay (Invitrogen, Burlington, ON). Cell density and homogeneity were also evaluated via crystal violet staining, followed by image capture.
SMC survival on ePTFE membranes.
To assess cell survival on the more realistic ePTFE membranes (100 μm thick, Zeus, Orangeburg, SC), direct counting of nuclei was performed. SMC were left to adhere on ePTFE discs for 24h. The surfaces were rinsed with PBS and serum-free medium was added. After 4 and 7 days, nuclei were stained. [17] Three images were captured for each sample using fluorescence microscopy, and cells were counted on each image. After 7 days, cells were fixed in paraformaldehyde and stained, [18] before observation via confocal microscopy (Olympus FV1000MPE).
Durability of the coatings
The EGF surface density of LP/CS/EGF coatings on ePTFE was evaluated by direct ELISA immediately after preparation, or after 1 day, 1 week and 1 month under three different storage conditions (dry, at room temperature, RT, or 4˚C; and in PBS at 37˚C) using an ELISA kit (R&D Systems, Minneapolis, MN). In addition, the bioactivity of the coating after 1 month was directly tested by cell survival experiments.
Coating transfer onto stent-grafts
The bioactive LP/CS/EGF coating was created on commercial SG from Atrium Medical
Corp., which consists of a tubular structure formed by two ePTFE layers encapsulating a stainless steel stent (Advanta V12, 6 mm diameter, 59 mm length, Atrium Medical Corp.,
Hudson, NH). Atrium SG were deployed using a balloon catheter, then inserted on top of a rotatable ceramic cylinder in the plasma deposition chamber. The coating was created as described above, so as to obtain a uniform 150 nm coating thickness on the outer surface. CS and EGF were successively grafted by immersion in the solutions just prior SG implantation under a sterile hood. The SGs were disinfected by immersion in EtOH 70% v/v for 5 minutes between CS and EGF grafting. Coated and control SG were left to dry under a sterile hood and placed in sterile tubes for transportation to the operation room.
In vivo implantation procedure
Preliminary in vivo testing of LP/CS/EGF coatings was performed in a canine bilateral iliac aneurysm model that reproduces persistent type I endoleaks after EVAR. [15] All procedures were approved by the institutional animal committee, in accordance with the guidelines of the Canadian Council on Animal Care, and performed under general anesthesia. Three mongrel dogs weighing 25-30 kg were subjected to surgical construction of bilateral iliac aneurysms without collateral, using an autologous jugular vein patch as already described in details. [16] After a recovery period of 8 weeks, the SG was inserted by a carotid approach under fluoroscopy, and expanded to 110% of the nominal arterial diameter (median 6 mm). In each dog, a LP/CS/EGF-modified SG was randomly implanted in one aneurysm, a control (unmodified) SG being implanted in the contralateral aneurysm. On both sides, plastic deformation of the SG was created at its proximal end by inflating a 3.5 mm diameter Savvy balloon catheter (Cordis Corp.) alongside the SG. [15] This formed a type I endoleak in all aneurysms, with inflow occurring through the misfit (~1-2 mm gap) at the proximal neck, as confirmed by angiography. Heraeus-Kulzer, Armonk, NY, USA), cut, and polished into 30 µm sections that were then stained with hematoxylin and eosin.
Statistical analysis
Results are expressed as mean ± standard deviation. Statistics were assessed by one-way ANOVA with Tukey's HSD post-hoc testing. For continuous variables measured in aneurysms implanted with active and control SGs, a paired student t-test with equal variances was used, p-values less than 0.05 being considered significant.
Results

Coating characterization and stability
As expected, LP deposition on PTFE led to an increase in nitrogen content on the surface ( (Fig. 3) . This explains the stable number of cells on ePTFE, despite their evident lack of interaction with the hydrophobic surface. In contrast, cells were well spread and homogeneously distributed on coated surfaces.
Fig. 3. Confocal microscope images of SMC after 7 days. Nuclei was stained with Hoescht 33342 (blue) and actin cytoskeletons with phalloidin-Alexa 488 (green). Cell morphology was drastically different on bare vs. modified material: cells formed large clusters on ePTFE, while they were well spread and homogeneously distributed on coated surfaces. Scale bars: 150 µm. (n=4).
Cell survival tests performed on coatings stored for 1 month showed similar results as fresh coatings. Cell survival after 7 days in serum-free medium was 146 ± 55% after storage in air at RT, 155 ± 39% after storage at 4°C, and 165 ± 49% after storage in PBS at 37°C, compared with 166 ± 62% on fresh surfaces (p>0.5). This confirms the stability of the coating.
Significantly higher cell survival was also demonstrated, with both SMC and fibroblasts, on coated PET substrates compared with unmodified controls ( Fig. E3 and E4 ; available online at www.jvir.org)
In vivo study
A homogeneous coating was then successfully created on the commercial SG ( Figure E5 ) before in vivo implantation in iliac aneurysms. Three months after implantation, no SG migration was observed, and all SG remained patent, as confirmed by CT-scan.
Endoleaks, characterized by well-defined empty areas on histology slides and bright areas on contrast-enhancement CT-scan ( Fig. 4a and Fig.E6 ), persisted in all aneurysms at three months. However, the portion of aneurysm corresponding to healed tissue was significantly greater in the presence of LP/CS/EGF coating (Fig. 5 , P<.02), and portions consisting of leak or fresh thrombus were lower for those aneurysms that were treated with the bioactive SG (Fig. 4b) . However, no definite conclusion should be drawn, since the number of samples was small (n=3) and results varied significantly from one animal to another.
Fig. 4 (a) Example of endoleaks from dog #1, bioactive SG, detected on CT-Scan (left) and histological section stained by HPS (right). (b) Transverse tissue sections taken at the middle of aneurysms for each dog, with control (first row) or bioactive SG (second row). Leak are indicated by double arrows and fresh thrombus by single dotted arrows. Scale bars: 5 mm. n.b. some post-mortem intraluminal thrombus is present in the lumen.
Bioactive SG displayed visibly smaller leaks and less fresh thrombus compared to control SG. 
Discussion
Recently, several non-bioactive devices have been developed to prevent endoleaks (including type I), using polymer-injectable structures that either provide on-site fitting at the proximal neck, [19] or that fill the whole cavity [20] . While these structures may allow better initial sealing and adaptation of the SG structure to the vessel anatomy, they do not protect from progression of aneurysmal degeneration at the necks and do not promote biological fixation of SG into the vessel wall. Indeed, the external cover of those devices is made of PTFE, and the in vitro cell culture tests performed here confirmed once again that this polymer fails to promote the cell-surface interactions that are required to achieve adequate cell adhesion and survival in a pro-apoptotic environment such as AAA. PTFE displays very low surface energy and extreme hydrophobicity [21] , and the near-complete lack of cell colonization observed in vitro illustrates the insufficient tissue ingrowth in vivo on ePTFE SG after EVAR [22] .
We believe that, in order to prevent late occurrence of endoleaks due to tissue degeneration at the aneurysm necks, it is crucial to achieve a sustained healing in the aneurysm sac and especially at the proximal and distal neck so as to achieve durable biological sealing. For that the SG external surface should favor smooth muscle cell as well as fibroblast adhesion and survival. Indeed, those two cell types play an important role in vascular remodeling following injury [23] .
Physico-chemical surface modifications alone do not lead to targeted cell responses as opposed to modifications with biological factors [24] . This was illustrated here, where the amine-rich polymer (LP) increased initial cell adhesion, but was ineffective to achieve adequate cell survival. A coating with tailored bioactive properties is needed to prevent cell apoptosis in the SG landing zones, and possibly to stop the disease progression at the aneurysm neck. Our approach has therefore been to immobilize pro-survival biomolecules, CS and EGF, on the external polymer surface of the SG.
In vitro results showed significant increase in the survival of both human SMC and fibroblasts. Interestingly and of considerable importance, the present coating maintained its bioactivity over a one-month storage period at various temperatures. The persistence of coating bioactivity is crucial to any clinical application, since a commercial bioactive SG will need to possess relatively long shelf life to accommodate inevitable delays between production and implantation. Moreover, good stability of the biomolecules prevent their leakage and undesirable effects on remote tissues.
In vivo results strongly suggest that our coating improves healing around the SG and minimizes the fresh thrombus and endoleak area, even though the number of animals in our present study was rather limited (n=3, with 2 aneurysms per animal). No complication or reduction of the SG internal lumen due to neointimal formation was observed, in contrast with other studies, where bioactive SG were found to induce partial stenosis [25] . However, the bioactive coating did not lead to complete healing of the cavity or to total sealing, as initially created endoleaks persisted even with the coated SG.
These results therefore appear mitigated, but they may be explained by the type of model used in this study, probably not the most appropriate to test our hypothesis. The limitations of our model are i) the creation of large endoleaks immediately after implantation; ii) the absence of a pathological vessel in our vein-patch model.
Indeed, large endoleaks were created after SG implantation. The persistent flow into the cavity tended to impede the important interactions between the bioactive coating and cells of the surrounding vessel wall. For a potential clinical use of our bioactive SG, in cases presenting a deficient SG apposition, or late occurrence of type II endoleaks coming from collateral arteries, a concomitant strategy could be used, such as inflatable polymeric bags [20] or injection of embolizing gels [26] .
Additionally, the vein patch used in this study provides a geometrical aneurysm model, one with realistic flow conditions; however, this model is exempt of atherosclerosis and calcium deposits, it displays normal ECM, without inflammation and SMC depletion, unlike a real AAA [3] .
To further evaluate the effect of our present anti-apoptotic bioactive coating on tissue healing after EVAR, our in vivo model should be adapted to mimic damage related to ECM and SMC apoptosis, two key characteristics of AAA, and to suppress large type I endoleaks that have previously been created by deformation of the SG during implantation. To this end, aneurysms may be created using decellularized xenografts [27] , elastase infusion, calcium chloride or angiotensin-II perfusion [28] .
In conclusion, a bioactive coating based on chondroitin sulfate (CS) and epidermal growth factor (EGF) was shown to increase the survival of human vascular smooth 
